These findings underscore the potential significance of specific genetic variants in the CYP1A2 gene in the etiology and progression of bladder cancer, suggesting that these polymorphisms may serve as genetic markers for assessing BLCA risk and warranting further investigation into their role in cancer development. This evidence concerns the gene CYP1A2 and bladder transitional cell carcinoma.